OptimizeRx Co. (NASDAQ:OPRX) Receives Average Rating of “Moderate Buy” from Analysts

OptimizeRx Co. (NASDAQ:OPRX) has earned an average recommendation of “Moderate Buy” from the nine research firms that are covering the stock, MarketBeat.com reports. Three investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $9.06.

A number of brokerages recently weighed in on OPRX. William Blair restated an “outperform” rating on shares of OptimizeRx in a report on Thursday, November 14th. Stifel Nicolaus lowered their price objective on shares of OptimizeRx from $13.00 to $8.00 and set a “buy” rating on the stock in a research note on Thursday, November 14th. Barclays dropped their target price on shares of OptimizeRx from $11.00 to $5.00 and set an “equal weight” rating on the stock in a report on Thursday, November 14th. Roth Mkm reiterated a “buy” rating and set a $16.00 price target (down previously from $20.00) on shares of OptimizeRx in a report on Thursday, November 14th. Finally, Stephens initiated coverage on OptimizeRx in a research note on Friday, December 20th. They issued an “equal weight” rating and a $5.50 price objective on the stock.

OptimizeRx Stock Down 1.5 %

OPRX stock opened at $5.35 on Tuesday. The company has a market cap of $98.55 million, a price-to-earnings ratio of -4.02 and a beta of 1.36. OptimizeRx has a twelve month low of $3.78 and a twelve month high of $16.65. The business has a 50 day moving average price of $5.10 and a two-hundred day moving average price of $6.79. The company has a quick ratio of 3.23, a current ratio of 3.23 and a debt-to-equity ratio of 0.29.

Insider Activity

In other news, CEO William J. Febbo bought 20,000 shares of the company’s stock in a transaction dated Thursday, December 12th. The stock was bought at an average price of $5.01 per share, with a total value of $100,200.00. Following the completion of the acquisition, the chief executive officer now owns 601,253 shares of the company’s stock, valued at $3,012,277.53. This represents a 3.44 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. 6.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On OptimizeRx

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. BNP Paribas Financial Markets increased its stake in OptimizeRx by 189.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company’s stock worth $28,000 after acquiring an additional 2,414 shares during the period. SG Americas Securities LLC acquired a new stake in shares of OptimizeRx during the 4th quarter worth $51,000. Quest Partners LLC increased its position in shares of OptimizeRx by 15,965.6% in the third quarter. Quest Partners LLC now owns 9,800 shares of the company’s stock worth $76,000 after purchasing an additional 9,739 shares during the period. Barclays PLC raised its stake in OptimizeRx by 358.5% in the third quarter. Barclays PLC now owns 26,934 shares of the company’s stock valued at $208,000 after purchasing an additional 21,060 shares in the last quarter. Finally, Squarepoint Ops LLC bought a new stake in OptimizeRx during the second quarter worth about $282,000. 76.47% of the stock is currently owned by institutional investors and hedge funds.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.